Rheumatoid Arthritis News

    Skip to content
    • Home
    • Treatments
      • Tofacitinib (Xeljanz)
    • Experimental Treatments
      • Piclidenoson
      • Kevzara (Sarilumab)
      • Baricitinib (Olumiant)
    • About Us
    • Contact Us
    •
      June 12, 2017August 24, 2022

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
    • June 7, 2017June 7, 2017

      Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
    • June 5, 2017June 5, 2017

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
    • June 2, 2017June 2, 2017

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
    • May 23, 2017May 23, 2017

      Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

      Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more
    Chronic Inflammation May Explain Heart Disease in Rheumatoid Arthritis
    November 28, 2016November 28, 2016

    Chronic Inflammation May Explain Heart Disease in Rheumatoid Arthritis

    News, rheumatoid arthritis
    Patients with rheumatoid arthritis have chronic inflammation in the heart, which may explain the common occurrence of heart disease in this patient group. The good news is it may be ... Read more
    Researchers Will Use Real-Life Experiences to Gauge Impact of RA-Specific Drug Therapies
    November 23, 2016November 23, 2016

    Researchers Will Use Real-Life Experiences to Gauge Impact of RA-Specific Drug Therapies

    News
    A new research project will investigate treatment and management options for rheumatoid arthritis (RA) by analyzing thousands of real-life experiences of RA-specific drugs. “By studying real-world experiences and stories, we can ... Read more
    Clinical Data Support Phase 3 Trials of Olokizumab for Rheumatoid Arthritis, R-Pharm Reports
    November 22, 2016November 22, 2016

    Clinical Data Support Phase 3 Trials of Olokizumab for Rheumatoid Arthritis, R-Pharm Reports

    News
    R-Pharm recently reported positive results from Phase 2 clinical trials of olokizumab for the treatment of rheumatoid arthritis, supporting the drug’s move into Phase 3 testing now underway. The data was presented ... Read more
    Therapy for Autoimmune Diseases Like RA Shows Positive Results in Clinical Trial
    November 21, 2016November 21, 2016

    Therapy for Autoimmune Diseases Like RA Shows Positive Results in Clinical Trial

    News
    Phase 1 trial results of an investigative selective inhibitor drug demonstrated that single or multiple oral doses of the therapy are safe and well tolerated by healthy subjects. These results ... Read more
    Fewer RA Patients Who Took Remicade Quit Treatment Than Those Who Used Biosimilar CT-P13
    November 18, 2016November 19, 2016

    Fewer RA Patients Who Took Remicade Quit Treatment Than Those Who Used Biosimilar CT-P13

    News
    Treatment of rheumatoid arthritis (RA) with Remicade (infliximab) is associated with lower rates of discontinuation among patients, compared to treatment with CT-P13 (a biosimilar of infliximab), according to results presented by ... Read more
    Certain Rheumatoid Arthritis Patients Improved Faster with Baricitinib than Humira, Studies Show
    November 17, 2016November 19, 2016

    Certain Rheumatoid Arthritis Patients Improved Faster with Baricitinib than Humira, Studies Show

    News
    Treatment with the investigative drug baricitinib is more effective than Humira (adalimumab), an FDA-approved therapy, in improving joint pain, stiffness and tiredness in patients with rheumatoid arthritis (RA) who have an ... Read more
    Baricitinib’s Effectiveness in Treating RA Symptoms Supported in New Analyses of Phase 3 Trials
    November 16, 2016November 19, 2016

    Baricitinib’s Effectiveness in Treating RA Symptoms Supported in New Analyses of Phase 3 Trials

    News
    New data analyses of two Phase 3 clinical trials evaluating the investigational therapy baricitinib for the treatment of rheumatoid arthritis (RA) symptoms have revealed promising results compared to conventional synthetic ... Read more
    Pfizer Presents New Positive Results on Xeljanz for Rheumatoid Arthritis
    November 15, 2016November 19, 2016

    Pfizer Presents New Positive Results on Xeljanz for Rheumatoid Arthritis

    News
    Pfizer recently presented encouraging results on the effectiveness and safety of the company’s product Xeljanz (tofacitinib citrate) for the treatment of rheumatoid arthritis (RA). The data was presented at the ACR/ARHP Annual ... Read more
    Study of Genetic Variant Could Lead to Better Autoimmune Disorder Therapies
    November 14, 2016November 19, 2016

    Study of Genetic Variant Could Lead to Better Autoimmune Disorder Therapies

    News
    A new study led by a research team at Oxford University suggests that pharmaceutically copying a genetic variant of a key protein could be a potential therapeutic strategy for autoimmune diseases. ... Read more
    New Research Looks at Thousands of RA Personal Treatment Experiences in UK
    November 11, 2016November 19, 2016

    New Research Looks at Thousands of RA Personal Treatment Experiences in UK

    News
    A new research project will investigate treatment and management options for rheumatoid arthritis (RA) by analyzing thousands of real-life experiences with RA-specific drugs. “By studying real-world experiences and stories, we can start ... Read more

    Posts navigation

    Older posts
    Newer posts

    Never miss another RA update.

    * indicates required
    Bionews, Inc.
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

    Recent Posts

    • Diplomat selling Kevzara

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      June 12, 2017

    • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      June 7, 2017

    • Truxima, a biosimilar of rituximab

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      June 5, 2017

    • triple therapy

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      June 2, 2017

    • About Us
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Rheumatoid Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2025 All rights reserved.